Innovative Bispecific Nanobody Targeting CD40 and FAP for Colorectal Cancer Therapy
VHH-P533 is an advanced therapeutic candidate designed as a humanized nanobody bispecific antibody, currently in the Biological Testing stage of development. This molecule precisely targets the CD40 molecule (CD40) expressed primarily on immune cells and fibroblast activation protein alpha (FAP), which is highly associated with tumor stromal remodeling. With its ability to simultaneously engage both CD40 molecule (CD40) and fibroblast activation protein alpha (FAP), VHH-P533 offers a novel approach for modulating key pathways implicated in colorectal cancer progression. Its structure and dual-targeting capability position it as a promising option in future colorectal cancer interventions.
| Candidate | VHH-P533 |
| Target | CD40 molecule (CD40) fibroblast activation protein alpha (FAP) |
| Modality | humanized bispecific VHH |
| Indication | Colorectal Cancer |
Licensing Opportunity
VHH-P533 is currently open for licensing and collaborative partnerships. We welcome inquiries from industry partners interested in advancing bispecific therapeutics for colorectal cancer.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P533 |
Modality
VHH-P533 is a bispecific therapeutic format consisting of an anti-FAP monoclonal IgG1 kappa antibody containing engineered Fc mutations, fused at both C-terminal ends to humanized anti-CD40 nanobodies via flexible (GGGGS)2 linkers. The inclusion of nanobodies, which are single-domain antibodies characterized by their small molecular size and robust stability, enhances tissue penetration and tumor accessibility—traits particularly valuable in solid tumor environments like colorectal cancer. The bispecific structure supports simultaneous engagement of tumor stroma (via FAP) and immune modulation (via CD40), optimizing the therapeutic window and offering innovative strategies to overcome tumor resistance mechanisms.
Target
VHH-P533 targets both CD40 and FAP, two molecules of strategic relevance in colorectal cancer. CD40 is a cell-surface receptor mainly present on antigen-presenting immune cells such as dendritic cells and B cells, crucial for activating adaptive immune responses. FAP is a serine protease highly expressed in cancer-associated fibroblasts within tumor stroma and rarely found in normal adult tissues. The dual engagement of CD40 and FAP is a promising approach in solid tumors: targeting CD40 can enhance anti-tumor immune responses, while FAP targeting disrupts stromal barriers, improving immune infiltration. Therefore, the strategic design of VHH-P533 to engage both CD40 and FAP positions it with distinct potential in reshaping the tumor microenvironment and potentiating colorectal cancer therapies.
Mechanism of Action
VHH-P533 exerts its anti-cancer effects by jointly modulating both FAP and CD40 pathways. The anti-FAP component interferes with the tumor-supportive stromal microenvironment, potentially disrupting fibroblast-mediated tumor growth and invasion. Simultaneously, the anti-CD40 nanobody moieties engage immune cells to stimulate signal transduction that activates anti-tumor immunity. By acting as a signal transduction modulator, this bispecific format has the capacity to coordinate immune activation with stromal remodeling. The modular nanobody platform utilized in VHH-P533 also offers the opportunity for future expansion into other therapeutic modes, such as antibody-drug conjugates (ADCs) and additional bispecific designs, broadening the scope of immuno-oncology applications.
Colorectal Cancer
Colorectal cancer is one of the most prevalent malignancies worldwide, with consistently high incidence and mortality rates. Epidemiological evidence highlights its significant public health burden, particularly in developed regions and aging populations. Standard treatments include surgical resection, chemotherapy, radiotherapy, and more recently, targeted therapies. However, recurrence, metastasis, and resistance to current modalities continue to present major clinical challenges. The tumor microenvironment, characterized by stromal desmoplasia and immune exclusion, is recognized as a critical barrier to effective therapy. VHH-P533, by dually targeting CD40 and FAP, has the potential to address unmet needs in colorectal cancer treatment through enhancing immune response and disrupting the tumor stroma. This makes VHH-P533 a compelling candidate for future therapeutic advancement in this field.